局限或局部晚期前列腺癌常规与低分次放疗的系统综述与荟萃分析
该系统综述与荟萃分析纳入10项III期随机试验共8146例局限或局部晚期前列腺癌患者,比较常规放疗与低分次放疗的疗效与毒性。两组在生化失败、生化/临床失败、总死亡率、前列腺癌特异性死亡率及≥2级泌尿生殖毒性和晚期胃肠道毒性方面均无显著差异,但低分次放疗的急性胃肠道毒性发生率显著更高。
要点
- 低分次放疗与常规放疗在肿瘤学结局上无显著差异。
- 低分次放疗的急性胃肠道毒性风险显著高于常规放疗。
- 雄激素剥夺治疗比例和精囊是否包含在临床靶区中影响急性胃肠道毒性。
核心结论
- 低分次放疗在局限或局部晚期前列腺癌中提供与常规放疗相似的治疗结局,但急性胃肠道毒性风险显著更高。
研究设计与样本
- 从5个数据库提取599篇摘要,按PRISMA指南筛选。
- 仅纳入比较常规放疗与低分次放疗的III期随机试验,且随访数据至少5年。
- 共纳入来自9项研究的10个试验,总计8146例患者(常规放疗3520例,低分次放疗4626例;1项研究比较2种低分次方案与共同常规方案)。
主要发现
- 两组患者特征无显著差异,但放疗参数差异显著(P<.001)。
- 雄激素剥夺治疗使用率在两组中均为0%至100%(均值±标准差:常规放疗与低分次放疗均为43.3%±43.6%;P=NS)。
- 生化失败、生化/临床失败、总死亡率、前列腺癌特异性死亡率、急性泌尿生殖毒性、晚期泌尿生殖和胃肠道毒性的OR、RR和RD均不显著。
- 常规放疗的急性胃肠道毒性发生率低9.1%(RD 0.091;OR 1.687;RR 1.470;P<.001 for all)。
- 亚组分析显示,雄激素剥夺治疗≤66.8% vs >66.8%(RD 0.052 vs 0.136;P=.008)和精囊完全包含在临床靶区<76% vs ≥76%(RD 0.034 vs 0.108;P<.001)显著影响低分次放疗的急性胃肠道毒性发生率。
关键数值与推荐
- 急性胃肠道毒性:常规放疗较低分次放疗RD 0.091(OR 1.687;RR 1.470;P<.001 for all)。
- 雄激素剥夺治疗≤66.8% vs >66.8%的急性胃肠道毒性RD分别为0.052 vs 0.136(P=.008)。
- 精囊完全包含在临床靶区<76% vs ≥76%的急性胃肠道毒性RD分别为0.034 vs 0.108(P<.001)。
临床怎么用
- 低分次放疗可作为局限或局部晚期前列腺癌的选项,缩短总治疗时间并方便患者。
- 需仔细考虑雄激素剥夺治疗比例和精囊是否包含在临床靶区等变量,以降低急性胃肠道毒性风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A systematic review and meta-analysis were conducted to evaluate the therapeutic outcomes of conventional radiation therapy (CRT) and hypofractionated radiation therapy (HRT) for localized or locally advanced prostate cancer (LLPCa). METHODS AND MATERIALS: A total of 599 abstracts were extracted from 5 databases and screened in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Only phase III trials randomized between CRT and HRT in LLPCa with a minimum of 5 years of follow-up data were considered. The evaluated endpoints were biochemical failure, biochemical and/or clinical failure, overall mortality, prostate cancer-specific mortality, and both acute and late gastrointestinal (GI) and genitourinary (GU) (grade ≥2) toxicity. RESULTS: Ten trials from 9 studies, with a total of 8146 patients (CRT, 3520; HRT, 4626; 1 study compared 2 HRT schedules with a common CRT regimen), were included in the evaluation. No significant differences were found in the patient characteristics between the 2 arms. However, the RT parameters differed significantly between CRT and HRT (P<.001 for all). The use of androgen deprivation therapy varied from 0% to 100% in both groups (mean ± standard deviation 43.3% ± 43.6% for CRT vs HRT; P=NS). The odds ratio, risk ratio, and risk difference (RD) between CRT and HRT for biochemical failure, biochemical and/or clinical failure, overall mortality, prostate cancer-specific mortality, acute GU toxicity, and late GU and GI toxicities were all nonsignificant. Nevertheless, the incidence of acute GI toxicity was 9.1% less with CRT (RD 0.091; odds ratio 1.687; risk ratio 1.470; P<.001 for all). On subgroup analysis, the patient groups with ≤66.8% versus >66.8% androgen deprivation therapy (RD 0.052 vs 0.136; P=.008) and <76% versus ≥76% full seminal vesicles in the clinical target volume (RD 0.034 vs 0.108; P<.001) were found to significantly influence the incidence of acute GI toxicity with HRT. CONCLUSIONS: HRT provides similar therapeutic outcomes to CRT in LLPCa, except for a significantly greater risk of acute GI toxicity. HRT enables a reduction in the overall treatment time and offers patient convenience. However, the variables contributing to an increased risk of acute GI toxicity require careful consideration.
引用
- Datta NR, Stutz E, Rogers S, et al. Conventional Versus Hypofractionated Radiation Therapy for Localized or Locally Advanced Prostate Cancer: A Systematic Review and Meta-analysis along with Therapeutic Implications. Int J Radiat Oncol Biol Phys. 2017. PMID: 29280452. doi:10.1016/j.ijrobp.2017.07.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。